RxDoctor Payments Data

Pritam Polkampally, MD

Interventional Cardiology · McDonough, GANPI 1487753877

Payments from drug & device makers

$3,020in general payments, 2019–2025

Across 134 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$421
  • Penumbra, Inc.$371
  • Novartis$299
  • E.r. Squibb & Sons, L.L.C.$286
  • Boston Scientific$274
  • AstraZeneca$260
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,90096%
  • Education$1194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,020 in reported general payments places this provider in the 15th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$641,703
Medicare patients
1,984
Services billed
6,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban458$463,475
BrilintaTicagrelor140$123,459
XareltoRivaroxaban58$68,211
EntrestoSacubitril/Valsartan51$59,417
Repatha SureclickEvolocumab14$9,995
Atorvastatin Calcium584$5,064
Metoprolol Tartrate791$2,934
Potassium Chloride268$2,883
Prasugrel Hcl34$2,767
Hydralazine Hcl130$2,132
Carvedilol314$2,048
Lisinopril402$1,910
Metoprolol Succinate154$1,670
ClopidogrelClopidogrel Bisulfate201$1,629
Furosemide406$1,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$463,475458 claims
AstraZenecaBrilinta$260$123,459140 claims
Johnson & JohnsonXarelto$421$68,21158 claims
NovartisEntresto$299$59,41751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in McDonough

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →